Tsutsui T
Department of Pharmacology, School of Dentistry, Tokyo, Nippon Dental University, Japan.
Nihon Yakurigaku Zasshi. 1997 Jul;110(1):1-9. doi: 10.1254/fpj.110.1.
Estrogens are clearly carcinogenic in humans and rodents, but the mechanisms by which these hormones induce cancer are only partially understood. Stimulation of cell proliferation and gene expression by binding to the estrogen receptor is one important mechanism in hormonal carcinogenesis; however, estrogenicity is not sufficient to explain the carcinogenic activity of all estrogens because some estrogens are not carcinogenic. Estrogens are nonmutagenic in many assays, but exhibit specific types of genotoxic activity under certain conditions. We have studied extensively the mechanisms by which estrogens induce neoplastic transformation in a model in vitro system. Diethylstilbestrol (DES) and 17 beta-estradiol (E2) and their metabolites induce morphological and neoplastic transformation of Syrian hamster embryo (SHE) cells that express no measurable levels of estrogen receptor. The estrogens induce DNA adduct formation that is detected by 32P-postlabeling. DNA adduct formation is detected in cells treated with DES, but not in cells treated with either alpha- or beta-dienestrol. Similarly, morphological transformation of SHE calls is induced by treatment with DES, but not by treatment with alpha- or beta-dienestrol. Exposure of SHE treatment cells to E2 and its metabolites 2-hydroxyestradiol and 4-hydroxyestradiol leads to covalent DNA adduct formation, corresponding to the induction of cell transformation. Induction of morphological transformation of SHE cells by estrogens correlates well with the ability of estrogens to induce DNA adduct formation. DNA damage caused by DNA adduct formation may be important in hormonal carcinogenesis. It is clear that hormones affect carcinogenesis by epigenetic mechanisms such as stimulation of cell proliferation of estrogen-dependent target cells and reprogramming of cellular differentiation and gene expression. In addition, significant evidence exists that certain estrogens can also cause genetic alterations by mechanisms not involving the classic estrogen receptor. These findings indicate that hormonal carcinogenesis is most likely a result of the interplay of both genetic and epigenetic factors.
雌激素在人类和啮齿动物中具有明确的致癌性,但这些激素诱发癌症的机制仅得到部分理解。通过与雌激素受体结合来刺激细胞增殖和基因表达是激素致癌作用中的一个重要机制;然而,雌激素活性不足以解释所有雌激素的致癌活性,因为有些雌激素并不致癌。在许多检测中,雌激素无致突变性,但在某些条件下会表现出特定类型的基因毒性活性。我们已广泛研究了雌激素在体外模型系统中诱发肿瘤转化的机制。己烯雌酚(DES)、17β-雌二醇(E2)及其代谢产物可诱导叙利亚仓鼠胚胎(SHE)细胞发生形态学和肿瘤转化,而这些细胞中未检测到可测量水平的雌激素受体。雌激素可诱导DNA加合物形成,这可通过32P后标记法检测到。在用DES处理的细胞中可检测到DNA加合物形成,但在用α-或β-双烯雌酚处理的细胞中未检测到。同样,用DES处理可诱导SHE细胞发生形态学转化,但用α-或β-双烯雌酚处理则不会。将SHE处理细胞暴露于E2及其代谢产物2-羟基雌二醇和4-羟基雌二醇会导致共价DNA加合物形成,这与细胞转化的诱导相对应。雌激素诱导SHE细胞发生形态学转化的能力与雌激素诱导DNA加合物形成的能力密切相关。DNA加合物形成所导致的DNA损伤在激素致癌作用中可能很重要。显然,激素通过表观遗传机制影响致癌作用,如刺激雌激素依赖性靶细胞的细胞增殖以及细胞分化和基因表达的重编程。此外,有大量证据表明,某些雌激素还可通过不涉及经典雌激素受体的机制导致基因改变。这些发现表明,激素致癌作用很可能是遗传和表观遗传因素相互作用的结果。